1 |
Ogawa M, Takakura H. Photoimmunotherapy: A new cancer treatment using photochemical reactions [J]. Bioorg Med Chem, 2021, 43: 116274.
|
2 |
Mitsunaga M, Ogawa M, Kosaka N, et al. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules [J]. Nat Med, 2011, 17(12): 1685-1691.
|
3 |
Okuyama S, Nagaya T, Sato K, et al. Interstitial near-infrared photoimmunotherapy: effective treatment areas and light doses needed for use with fiber optic diffusers [J]. Oncotarget, 2018, 9(13): 11159-11169.
|
4 |
李芳, 辛俊勃, 施秦, 等. 肿瘤的近红外光免疫治疗研究进展 [J]. 中国药科大学学报 [J]. 2020, 51(6): 664-674.
|
5 |
Yamada M, Matsuoka K, Sato M, et al. Recent advances in localized immunomodulation technology: application of NIR-PIT toward clinical control of the local immune system [J]. Pharmaceutics, 2023, 15(2).
|
6 |
Kobayashi H, Choyke PL. Near-infrared photoimmunotherapy of cancer [J]. Acc Chem Res, 2019, 52(8): 2332-9.
|
7 |
Ogawa M, Tomita Y, Nakamura Y, et al. Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity [J]. Oncotarget, 2017, 8(6): 10425-36.
|
8 |
Chen Z, Liu L, Liang R, et al. Bioinspired hybrid protein oxygen nanocarrier amplified photodynamic therapy for eliciting anti-tumor immunity and abscopal effect [J]. ACS nano, 2018, 12(8): 8633-45.
|
9 |
Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity [J]. Nat Rev Cancer, 2006, 6(7): 535-45.
|
10 |
Mohiuddin TM, Zhang C, Sheng W, et al. Near infrared photoimmunotherapy: a review of recent progress and their target molecules for cancer therapy [J]. Int J Mol Sci, 2023, 24(3).
|
11 |
Sano K, Nakajima T, Choyke PL, et al. Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors [J]. ACS nano, 2013, 7(1): 717-724.
|
12 |
Maruoka Y, Wakiyama H, Choyke PL, et al. Near infrared photoimmunotherapy for cancers: A translational perspective [J]. EBioMedicine, 2021, 70: 103501.
|
13 |
董佳琳, 荆慧. 近红外光免疫治疗在乳腺癌治疗中的研究进展 [J]J 中国肿瘤临床, 2023, 50(22): 1164-1167.
|
14 |
Lum YL, Luk JM, Staunton DE, et al. Cadherin-17 targeted near-infrared photoimmunotherapy for treatment of gastrointestinal cancer [J]. Mol Pharm, 2020, 17(10): 3941-3951.
|
15 |
Tang Q, Nagaya T, Liu Y, et al. 3D mesoscopic fluorescence tomography for imaging micro-distribution of antibody-photon absorber conjugates during near infrared photoimmunotherapy in vivo [J]. J Control Release, 2018, 279: 171-180.
|
16 |
Tang Q, Nagaya T, Liu Y, et al. Real-time monitoring of microdistribution of antibody-photon absorber conjugates during photoimmunotherapy in vivo [J]. J Control Release, 2017, 260: 154-163.
|
17 |
Wang C, Gu B, Qi S, et al. Boosted photo-immunotherapy via near-infrared light excited phototherapy in tumor sites and photo-activation in sentinel lymph nodes [J]. Nanoscale Adv, 2024, 6(8): 2075-2087.
|
18 |
金凯, 郭驹, 唐婷, 等近红外光免疫疗法在恶性肿瘤中的研究进展 [J]. 广西医学, 2022, 44(9): 1031-1035.
|
19 |
Moore LS, de Boer E, Warram JM, et al. Photoimmunotherapy of residual disease after incomplete surgical resection in head and neck cancer models [J]. Cancer Med, 2016, 5(7): 1526-1534.
|
20 |
Nagaya T, Nakamura Y, Okuyama, et al. Syngeneic mouse models of oral cancer are effectively targeted by anti-CD44-Based NIR-PIT [J]. Mol Cancer Res, 2017, 15(12): 1667-1677.
|
21 |
Maruoka Y, Furusawa A, Okada R, et al. Combined cd44- and cd25-targeted near-infrared photoimmunotherapy selectively kills cancer and regulatory T cells in syngeneic mouse cancer models [J]. Cancer Immunol Res, 2020, 8(3): 345-355.
|
22 |
Kato T, Okada R, Furusawa A, et al. Simultaneously combined cancer cell- and CTLA4-targeted NIR-PIT causes a synergistic treatment effect in syngeneic mouse models [J]. Mol Cancer Ther, 2021, 20(11): 2262-2273.
|
23 |
Sato H, Noma K, Ohara T, et al. Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in the tumor microenvironment [J]. Sci Rep, 2022, 12(1): 20152.
|
24 |
Hartmans E, Linssen MD, Sikkens C, et al. Tyrosine kinase inhibitor induced growth factor receptor upregulation enhances the efficacy of near-infrared targeted photodynamic therapy in esophageal adenocarcinoma cell lines [J]. Oncotarget, 2017, 8(18): 29846-29856.
|
25 |
Katsube R, Noma K, Ohara T, et al. Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer [J]. Sci Rep, 2021, 11(1): 1693.
|
26 |
Emami F, Pathak S, Nguyen TT, et al. Photoimmunotherapy with cetuximab-conjugated gold nanorods reduces drug resistance in triple negative breast cancer spheroids with enhanced infiltration of tumor-associated macrophages [J]. J Control Release, 2021, 329: 645-664.
|
27 |
Nagaya T, Gorka AP, Nani RR, et al. Molecularly targeted cancer combination therapy with near-infrared photoimmunotherapy and near-infrared photorelease with duocarmycin-antibody conjugate [J]. Mol Cancer Ther, 2018, 17(3): 661-670.
|
28 |
Jin J, Krishnamachary B, Mironchik Y, et al. Phototheranostics of CD44-positive cell populations in triple negative breast cancer [J]. Sci Rep, 2016, 6: 27871.
|
29 |
Yamaguchi H, On J, Morita T, et al. Combination of near-infrared photoimmunotherapy using trastuzumab and small protein mimetic for HER2-positive breast cancer [J]. Int J Mol Sci, 2021, 22(22): 12213.
|
30 |
Yamaguchi H, Pantarat N, Suzuki T, et al. Near-infrared photoimmunotherapy using a small protein mimetic for HER2-overexpressing breast cancer [J]. Int J Mol Sci, 2019, 20(23): 5835.
|
31 |
Fukushima H, Kato T, Furusawa A, et al. Intercellular adhesion molecule-1-targeted near-infrared photoimmunotherapy of triple-negative breast cancer [J]. Cancer Sci, 2022, 113(9): 3180-3192.
|
32 |
Jin J, Barnett JD, Krishnamachary B, et al. Evaluating near-infrared photoimmunotherapy for targeting fibroblast activation protein-α expressing cells in vitro and in vivo [J]. Cancer Sci, 2023, 114(1): 236-246.
|
33 |
Nishimura T, Mitsunaga M, Ito K, et al. Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT [J]. Gastric Cancer, 2020, 23(1): 82-94.
|
34 |
Choi ES, Kim H, Kim HP, et al. CD44v8-10 as a potential theranostic biomarker for targeting disseminated cancer cells in advanced gastric cancer [J]. Sci Rep, 2017, 7(1): 4930.
|
35 |
Shirasu N, Yamada H, Shibaguchi H, et al. Potent and specific antitumor effect of CEA-targeted photoimmunotherapy [J]. Int J Cancer, 2014, 135(11): 2697-2710.
|
36 |
Nakamura Y, Ohler ZW, Householder D, et al. Near infrared photoimmunotherapy in a transgenic mouse model of spontaneous epidermal growth factor receptor (EGFR)-expressing lung cancer [J]. Mol Cancer Ther, 2017, 16(2): 408-414.
|
37 |
Takahashi K, Taki S, Yasui H, et al. HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer [J]. Cancer Med, 2021, 10(24): 8808-8819.
|
38 |
Sato K, Nagaya T, Mitsunaga M, et al. Near infrared photoimmunotherapy for lung metastases [J]. Cancer Lett, 2015, 365(1): 112-121.
|
39 |
Nagaya T, Nakamura Y, Sato K, et al. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody [J]. Oncotarget, 2017, 8(5): 8807-8817.
|
40 |
Isobe Y, Sato K, Nishinaga Y, et al. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer [J]. EBioMedicine, 2020, 52: 102632.
|
41 |
Li F, Mao C, Yeh S, et al. Combinatory therapy of MRP1-targeted photoimmunotherapy and liposomal doxorubicin promotes the antitumor effect for chemoresistant small cell lung cancer [J]. Int J Pharm, 2022, 625: 122076.
|
42 |
Li F, Mao C, Yeh S, et al. MRP1-targeted near infrared photoimmunotherapy for drug resistant small cell lung cancer [J]. Int J Pharm, 2021, 604: 120760.
|
43 |
Zhang C, Gao L, Cai Y, et al. Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model [J]. Biomaterials, 2016, 84: 1-12.
|
44 |
Okada R, Kato T, Furusawa A, et al. Local depletion of immune checkpoint ligand CTLA4 expressing cells in tumor beds enhances antitumor host immunity [J]. Adv Ther (Weinh), 2021, 4(5): 2000269.
|
45 |
Yasui H, Nishinaga Y, Taki S, et al. Near-infrared photoimmunotherapy targeting GPR87: Development of a humanised anti-GPR87 mAb and therapeutic efficacy on a lung cancer mouse model [J]. EBioMedicine, 2021, 67: 103372.
|
46 |
Hollandsworth HM, Amirfakhri S, Filemoni F, et al. Near-infrared photoimmunotherapy is effective treatment for colorectal cancer in orthotopic nude-mouse models [J]. PLoS One, 2020, 15(6): e0234643.
|
47 |
Wei D, Tao Z, Shi Q, et al. Selective photokilling of colorectal tumors by near-infrared photoimmunotherapy with a GPA33-targeted single-chain antibody variable fragment conjugate [J]. Mol Pharm, 2020, 17(7): 2508-2517.
|
48 |
Mączyńska J, Raes F, Da Pieve C, et al. Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy [J]. BMC Med, 2022, 20(1): 16.
|
49 |
Burley TA, Mączyńska J, Shah A, et al. Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment [J]. Int J Cancer, 2018, 142(11): 2363-2374.
|
50 |
Jing H, Weidensteiner C, Reichardt W, et al. Imaging and selective elimination of glioblastoma stem cells with theranostic near-infrared-labeled CD133-specific antibodies [J]. Theranostics, 2016, 6(6): 862-74.
|
51 |
Furusawa A, Okada R, Inagaki F, et al. CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model [J]. Oncoimmunology, 2022, 11(1): 2019922.
|
52 |
Wei W, Jiang D, Ehlerding EB, et al. CD146-targeted multimodal image-guided photoimmunotherapy of melanoma [J]. Adv Sci (Weinh), 2019, 6(9): 1801237.
|
53 |
Railkar R, Krane LS, Li QQ, et al. Epidermal growth factor receptor (EGFR)-targeted photoimmunotherapy (PIT) for the treatment of EGFR-expressing bladder cancer [J]. Mol Cancer Ther, 2017, 16(10): 2201-2214.
|
54 |
Siddiqui MR, Railkar R, Sanford T, et al. Targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) expressing bladder cancer using combination photoimmunotherapy (PIT) [J]. Sci Rep, 2019, 9(1): 2084.
|
55 |
Bou Kheir G, Aoun F, Roumeguere T. CD47 targeted near-infrared photo-immunotherapy: a promising tool combining monoclonal antibodies and photodynamics for treating human bladder cancer [J]. Transl Androl Urol, 2019, 8(6): 779-780.
|
56 |
Jin J, Sivakumar I, Mironchik Y, et al. PD-L1 near infrared photoimmunotherapy of ovarian cancer model [J]. Cancers (Basel), 2022, 14(3): 619.
|
57 |
Harada T, Nakamura Y, Sato K, et al. Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer [J]. Oncotarget. 2016 Nov 29;7(48):79408-79416.
|
58 |
Nagaya T, Nakamura Y, Okuyama S, et al. Near-infrared photoimmunotherapy targeting prostate cancer with prostate-specific membrane antigen (PSMA) antibody [J]. Mol Cancer Res, 2017, 15(9): 1153-1162.
|
59 |
Polikarpov DM, Campbell DH, Lund ME, et al. The feasibility of Miltuximab®-IRDye700DX-mediated photoimmunotherapy of solid tumors [J]. Photodiagnosis Photodyn Ther, 2020, 32: 102064.
|
60 |
Kim G, Gaitas A. Extracorporeal photo-immunotherapy for circulating tumor cells [J]. PLoS One, 2015, 10(5): e0127219.
|
61 |
Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma [J]. Nat Rev Dis Primers, 2020, 6(1): 92.
|
62 |
Zhang Y, Dong P, Yang L. The role of nanotherapy in head and neck squamous cell carcinoma by targeting tumor microenvironment [J]. Front Immunol, 2023, 14: 1189323.
|
63 |
Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J]. J Clin Oncol, 2005, 23(11): 2445-2459.
|
64 |
Nakano K. Progress of molecular targeted therapy for head and neck cancer in clinical aspects [J]. Mol Biomed, 2021, 2(1): 15.
|
65 |
Cognetti DM, Johnson JM, Curry JM, et al. Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma [J]. Head Neck, 2021, 43(12): 3875-3887.
|
66 |
Chen J, Zhou J, Lu J, et al. Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis [J]. BMC Cancer, 2014, 14: 15.
|
67 |
周欣, 张慧媛, 王淑静, 等. 非小细胞肺癌靶向PET显像的临床研究进展 [J/OL]. 中华临床医师杂志(电子版), 2021, 15(2): 123-128.
|
68 |
Wu J, Wang D. CLIC1 Induces drug resistance in human choriocarcinoma through positive regulation of MRP1 [J]. Oncol Res, 2017, 25(6): 863-871.
|
69 |
Zhang Y. Epidemiology of esophageal cancer [J]. World J Gastroenterol, 2013, 19(34): 5598-606.
|
70 |
Suntharalingam M, Winter K, Ilson D, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: The NRG oncology RTOG 0436 phase 3 randomized clinical trial [J]. JAMA Oncol, 2017, 3(11): 1520-1528.
|
71 |
Safran HP, Winter K, Ilson DH, et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial [J]. Lancet Oncol, 2022, 23(2): 259-269.
|
72 |
Stroes CI, Schokker S, Creemers A, et al. Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma: TRAP study [J]. J Clin Oncol, 2020, 38(5): 462-471.
|
73 |
Kashima H, Noma K, Ohara T, et al. Cancer-associated fibroblasts (CAFs) promote the lymph node metastasis of esophageal squamous cell carcinoma [J]. Int J Cancer, 2019, 144(4): 828-840.
|
74 |
Liu R, Li H, Liu L, et al. Fibroblast activation protein: A potential therapeutic target in cancer [J]. Cancer Biol Ther, 2012, 13(3): 123-129.
|
75 |
Tiernan JP, Perry SL, Verghese ET, et al. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting [J]. Br J Cancer, 2013, 108(3): 662-667.
|
76 |
Yamashita S, Kojima M, Onda N, et al. Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer [J]. Cancer Med, 2023, 12(4): 4579-4589.
|
77 |
Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype [J]. Curr Mol Med, 2012, 12(1): 96-110.
|
78 |
Nagaya T, Sato K, Harada T, et al. Near infrared photoimmunotherapy targeting EGFR positive triple negative breast cancer: Optimizing the conjugate-light regimen [J]. PLoS One, 2015, 10(8): e0136829.
|
79 |
Lu Y, Wang Y, Liu W, et al. Photothermal "nano-dot" reactivate "immune-hot" for tumor treatment via reprogramming cancer cells metabolism [J]. Biomaterials, 2023, 296: 122089.
|
80 |
Feng Y, Xu Y, Wen Z, et al. Cerium end-deposited gold nanorods-based photoimmunotherapy for boosting tumor immunogenicity [J]. Pharmaceutics, 2023, 15(4): 1309.
|
81 |
Chaux A, Cohen JS, Schultz L, et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues [J]. Human pathology, 2012, 43(10): 1590-1595.
|
82 |
Nagaya T, Okuyama S, Ogata F, et al. Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody [J]. Oncotarget, 2018, 9(27): 19026-19038.
|
83 |
Kim J. Looking into the clinical application of CD47-targeted near-infrared photoimmunotherapy for human bladder cancer treatment [J]. Transl Androl Urol, 2019, 8(Suppl 3): S322-S324.
|
84 |
Kiss B, van den Berg NS, Ertsey R, et al. CD47-targeted near-infrared photoimmunotherapy for human bladder cancer [J]. Clin Cancer Res, 2019, 25(12): 3561-3571.
|
85 |
Yang Y, Yan X, Li J, et al. CD47-targeted optical molecular imaging and near-infrared photoimmunotherapy in the detection and treatment of bladder cancer [J]. Mol Ther Oncolytics, 2022, 24: 319-330.
|
86 |
Coleman R, Hadji P, Body JJ, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Bone health in cancer: ESMO Clinical Practice Guidelines [J]. Ann Oncol, 2020, 31(12): 1650-1663.
|
87 |
Jimenez-Andrade JM, Mantyh WG, Bloom AP, et al. Bone cancer pain [J]. Ann N Y Acad Sci, 2010, 1198: 173-181.
|
88 |
Nakamura YA, Okuyama S, Furusawa A, et al. Near-infrared photoimmunotherapy through bone [J]. Cancer Sci, 2019, 110(12): 3689-3694.
|
89 |
Inagaki FF, Wakiyama H, Furusawa A, et al. Near-infrared photoimmunotherapy (NIR-PIT) of bone metastases [J]. Biomed Pharmacother, 2023, 160: 114390.
|
90 |
Nagaya T, Nakamura Y, Sato K, et al. Near infrared photoimmunotherapy of B-cell lymphoma [J]. Mol Oncol, 2016, 10(9): 1404-1414.
|
91 |
李莹, 胡德胜, 谭文勇. 光生物调节在管理抗肿瘤治疗毒性中的研究进展 [J]. 肿瘤防治研究, 2023, 50(10): 1004-1009.
|
92 |
Sato K, Watanabe R, Hanaoka H, et al. Comparative effectiveness of light emitting diodes (LEDs) and Lasers in near infrared photoimmunotherapy [J]. Oncotarget, 2016, 7(12): 14324-14335.
|
93 |
Pansare V, Hejazi S, Faenza W, et al. Review of long-wavelength optical and NIR imaging materials: contrast agents, fluorophores and multifunctional nano carriers [J]. Chem Mater, 2012, 24(5): 812-827.
|
94 |
Nagaya T, Okuyama S, Ogata F, et al. Near infrared photoimmunotherapy using a fiber optic diffuser for treating peritoneal gastric cancer dissemination [J]. Gastric Cancer, 2019, 22(3): 463-472.
|
95 |
Mitsunaga M, Nakajima T, Sano K, et al. Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate [J]. Bioconjug Chem, 2012, 23(3): 604-609.
|
96 |
Tsukamoto T, Fujita Y, Shimogami M, et al. Inside-the-body light delivery system using endovascular therapy-based light illumination technology [J]. EBioMedicine, 2022, 85: 104289.
|